Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. FUJIFILM Holdings Corporation
  6. News
  7. Summary
    4901   JP3814000000

FUJIFILM HOLDINGS CORPORATION

(4901)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eli Lilly in deal to supply COVID-19 drugs to low-income countries

10/08/2020 | 10:32pm EDT
FILE PHOTO: Eli Lilly logo is shown on one of their offices in San Diego

(Reuters) - Eli Lilly and Co said on Thursday it had entered into an agreement with the Bill & Melinda Gates Foundation for potential supply of its experimental antibody treatments for COVID-19 to low and middle-income countries.

As part of the deal, Lilly said it will make antibody therapies available to lower-income countries prior to April 2021, but did not elaborate on the number of doses. Separately, Fujifilm Holdings Corp said its facility in Denmark would manufacture treatments next year.

Lilly had previously said it would make one million doses of its single antibody treatment available by the end of the year, and another 50,000 doses of its dual-antibody therapy by the fourth quarter this year.

Lilly said its partners with which it is developing antibody therapies, including Canadian biotech company AbCellera Biologics Inc, had agreed to waive their royalties on the therapies distributed in low- and middle-income countries.

The drugmaker in September partnered with Amgen Inc to increase supply of its antibody therapies, a day after data showed that Lilly's single antibody therapy, LY-CoV555, helped cut hospitalization and emergency room visits for COVID-19 patients.

Fujifilm said in a statement it expects to begin manufacturing of Lilly's antibody therapy in April 2021. In June, the company said its subsidiary Fujifilm Diosynth Biotechnologies would double capacity at its Danish facility, which it has pledged to use in making COVID-19 treatments.

A dual-antibody combination also showed similar results on Wednesday. Lilly plans to seek U.S. emergency use authorization for that combination next month.

(Reporting by Manas Mishra in Bengaluru; Editing by Shailesh Kuber)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
AMGEN INC. -0.86% 238.68 Delayed Quote.4.71%
ELI LILLY AND COMPANY -1.65% 218.55 Delayed Quote.31.61%
FUJIFILM HOLDINGS CORPORATION 0.34% 7889 End-of-day quote.45.07%
All news about FUJIFILM HOLDINGS CORPORATION
06/14FUJIFILM  : North America Corporation, Graphic Systems Division Welcomes Packagi..
AQ
06/11FUJIFILM  : 'Art as an Essential Facet of Life and Community' - Fujifilm Announc..
AQ
06/09FUJIFILM  : Direct Edge Expands Capabilities, Increases Efficiencies, and Deligh..
AQ
05/31FUJIFILM  : Notice of Convocation
PU
05/27FUJIFILM  : Wako Pure Chemical launches “E484Q mutation detection kit&rdqu..
PU
05/24FUJIFILM  : Showcases Comprehensive Portfolio of Enterprise Imaging Solutions at..
AQ
05/18FUJIFILM  : Japan's Fujifilm says it can make new coronavirus variant detection ..
RE
05/18BAYER  : BlueRock, Fujifilm Cellular Dynamics to Co-Develop Cell Therapies for E..
MT
05/18FUJIFILM  : BlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis Therape..
PU
05/17FUJIFILM  : unit launches COVID-19 detection kit for Indian, Californian variant..
RE
More news
Financials
Sales 2021 2 179 B 19 776 M 19 776 M
Net income 2021 153 B 1 393 M 1 393 M
Net Debt 2021 170 B 1 543 M 1 543 M
P/E ratio 2021 20,1x
Yield 2021 1,25%
Capitalization 3 154 B 28 606 M 28 620 M
EV / Sales 2021 1,53x
EV / Sales 2022 1,38x
Nbr of Employees 73 906
Free-Float 73,9%
Chart FUJIFILM HOLDINGS CORPORATION
Duration : Period :
FUJIFILM Holdings Corporation Technical Analysis Chart | 4901 | JP3814000000 | MarketScreener
Technical analysis trends FUJIFILM HOLDINGS CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Average target price 8 007,14 JPY
Last Close Price 7 889,00 JPY
Spread / Highest target 26,8%
Spread / Average Target 1,50%
Spread / Lowest Target -21,4%
EPS Revisions
Managers and Directors
NameTitle
Shigetaka Komori Chairman & Group Chief Executive Officer
Kenji Sukeno President, Group COO & Representative Director
Takashi Iwasaki Director & Chief Technology Officer
Kunitaro Kitamura Independent Outside Director
Tatsuo Kawada Independent Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
FUJIFILM HOLDINGS CORPORATION45.07%28 493
ABBOTT LABORATORIES1.95%198 346
MEDTRONIC PLC6.89%168 458
BECTON, DICKINSON AND COMPANY-3.98%69 869
ALIGN TECHNOLOGY, INC.14.77%48 537
HOYA CORPORATION1.26%47 872